The Side Effects of Lung Cancer Treatment
Bonnie Addario, a lung cancer survivor, discusses toxicities involved during lung cancer treatment.
Watch
Vinegar as a Screening Tool in the U.S.
Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses the utility for vinegar as a screening tool in the U.S.
The Challenges of Treating Liver Cancer
Richard Finn, MD, from UCLA's Jonsson Comprehensive Cancer Center, discusses the difficulties of treating liver cancer.
Patient Response to Immunotherapy
Julie R. Brahmer, MD, Associate Professor, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses patient response to immunotherapy.
Effects of the Affordable Care Act
Ben Jones from McKesson Specialty Health discusses how the affordable care act will affect oncologists.
Sequencing and Combining Immunotherapies in Melanoma
Howard L. Kaufman, MD, says that the oncology community is in its infancy in terms of selecting and sequencing immunotherapies for patients with melanoma.
ALK inhibitors in Patients With NSCLC
Corey J. Langer, MD, from the Abramson Cancer Center, discusses recent advancements in treating an ALK mutation in patients with non-small cell lung cancer.
Surgery and Radiotherapy for Patients With Breast Cancer
Andrew D. Seidman, MD, from Memorial Sloan-Kettering Cancer Center, discusses breast cancer treatment with surgery and radiotherapy.
Afatinib in Patients With an EGFR Mutation
Giorgio V. Scagliotti, MD, PhD, from the University of Turin, San Luigi Hospital, Orbassano, Italy, discusses afatinib in patients with EGFR-mutated tumors.
T Cell Resistance to TGF-Beta in Lymphoma
Catherine Bollard, MBChB, MD, from the Baylor College of Medicine, discusses T cells and TGF-beta in Hodgkin's lymphoma and Non-Hodgkin lymphoma.
The Wnt Pathway and its Role in Colorectal Cancer
S. Gail Eckhardt, MD, Professor and Head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.
Gene Assays and the Treatment of Breast Cancer
Kathy S. Albain, MD, from Loyola University Chicago, discusses gene assays as they relate to the treatment of patients with breast cancer.
PROFILE 1007 Trial: Crizotinib vs Pemetrexed or Docetaxel in NSCLC
D. Ross Camidge, MD, PhD, comments on the subgroup analysis of the PROFILE 1007 trial, which looked at crizotinib versus either pemetrexed or docetaxel in NSCLC.
Improving Lung Cancer Drug Development
Tony S.K. Mok, BMSc, MD, FRCPC, from the Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.
Afatinib for Patients With EGFR Mutation
Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.
PROSTVAC in Castration-Resistant Prostate Cancer
James L. Gulley, MD, PhD, discusses how PROSTVAC works in patients with castration-resistant prostate cancer.
Clincal Trial Endpoints in Ovarian Cancer
Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.
Advances in the Treatment of Lung Cancer
David P. Carbone, MD, PhD, from the The Ohio State University Wexner Medical Center, discusses advances in the treatment of lung cancer.
MEK Inhibitors for the Treatment of Melanoma
Alex A. Adjei, MD, PhD, discusses the use of MEK inhibitors when treating patients with melanoma.
The E75 Vaccine for Breast Cancer
Elizabeth Mittendorf, MD, PhD, from the University of Texas MD Anderson Cancer Center, gives an overview of how the E75 vaccine works in breast cancer.
BTK Inhibition and the Mechanism of Action of Ibrutinib
Jennifer Woyach, MD, discusses Bruton's tyrosine kinase inhibition and the mechanism of action of ibrutinib.
Therapeutic Index of Targeted Therapies and Conventional Cytotoxics
Grace Dy, MD, from the Roswell Park Cancer Institute, discusses the therapeutic index of targeted therapies and conventional cytotoxics.
Drug Sequencing in Melanoma
Jeffrey A. Sosman, MD, from the Vanderbilt-Ingram Cancer Center, discusses drug sequencing for patients with melanoma at the 11th Annual International Congress on Targeted Therapies in Cancer.
CAR-Modified T Cells for the Treatment of Solid Tumors
Renier J. Brentjens, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the potential efficacy of CAR-modified T cells for the treatment of solid tumors.
The Efficacy of Immune Checkpoint Inhibitors
Roy S. Herbst, MD, PhD, from the Yale Cancer Center, describes immunotherapy as one of the most exciting advances in cancer care.
The Potential of HSP Inhibitors as Radiation Sensitizers
Laurie Gaspar, MD, from the University of Colorado School of Medicine, discusses the potential of heat shock protein (HSP) inhibitors as radiation sensitizers.
An Overview of the Treatment of Hematologic Malignancies
Julian Adams, PhD, from Infinity Pharmaceuticals, discusses PI3K inhibitors and chemotherapies for the treatment of hematologic malignancies.
CELLSEARCH Circulating Tumor Cell Test
Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, describes the CELLSEARCH® CTC Test, which allows for an assessment of patient prognosis.
The Impact of Sequestration
Richard L. Schilsky, MD, from the University of Chicago Comprehensive Cancer Center, discusses the impact that sequestration had on the FDA.
The Investigation of Immunotherapy in Lung Cancer
David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, discusses the exploration of immunotherapies as treatments for patients with advanced lung cancer.